Study on Reduced Chemotherapy and Monoclonal Antibody Therapy for Children with Neuroblastoma

Sponsor: Memorial Sloan Kettering Cancer Center

Sponsor score: 60
Inactive

ClinicalTrials ID:NCT06528496

Provider View

This clinical trial is exploring whether a treatment called N10, which involves reduced chemotherapy and monoclonal antibody therapy, is safe and effective for children with high-risk neuroblastoma, a type of cancer.

Patient Parameters

Program Overview

The aim of this study is to determine if the N10 treatment, which combines reduced chemotherapy with monoclonal antibody therapy, is a safe and effective option for children diagnosed with high-risk neuroblastoma, a serious form of cancer that affects nerve cells.

Eligibility Criteria

Inclusion Criteria

  • Diagnosed with neuroblastoma based on specific medical tests, such as tissue samples, bone marrow tests, or certain scan results.
  • Classified as high-risk neuroblastoma, which includes specific genetic markers or cancer stages.
  • Have received no more than one previous cycle of high-risk neuroblastoma chemotherapy.
  • Under 19 years of age.
  • Signed consent form acknowledging understanding of the study's experimental nature.

Exclusion Criteria

  • Severe problems with major organs, such as kidneys, heart, liver, brain, lungs, blood, or digestive system, that are more than mild.
  • Unable to follow the study's requirements.
  • Pregnant.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.